In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 51 to 100 of 382

TitleTypeExpected publication date
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Breast cancer guidelinesNICE guidelineTBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448Technology appraisal guidanceTBC
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]Technology appraisal guidance
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]Technology appraisal guidance
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Technology appraisal guidanceTBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]Technology appraisal guidanceTBC
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)Health technology evaluationTBC
Cardiometabolic disease prevention and treatment guidelinesNICE guidelineTBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580Technology appraisal guidance
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidanceTBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]Highly specialised technology
Chronic heart failure in adults: diagnosis and managementNICE guideline
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Technology appraisal guidanceTBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessmentHealth technology evaluationTBC
Colon cancer (adjuvant) - irinotecan [ID379]Technology appraisal guidanceTBC
Compression products for treating venous leg ulcers: late stage assessmentHealth technology evaluation
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitisInterventional procedures guidanceTBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Technology appraisal guidanceTBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Technology appraisal guidanceTBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]Technology appraisal guidance
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]Technology appraisal guidance
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [ID6452]Technology appraisal guidance
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]Technology appraisal guidanceTBC
DCVax-L for treating glioblastoma [ID836]Technology appraisal guidanceTBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Technology appraisal guidanceTBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Technology appraisal guidanceTBC
Delgocitinib for treating moderate to severe chronic hand eczema [ID6408]Technology appraisal guidance
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]Technology appraisal guidanceTBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]Technology appraisal guidance
Deutetrabenazine for treating tardive dyskinesia ID6550Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726Technology appraisal guidanceTBC
Diabetic retinopathy - ruboxistaurin [ID382]Technology appraisal guidanceTBC
Digital platforms to support cardiac rehabilitation: early value assessmentHealth technology evaluation
Digital self-help for eating disorders: early value assessmentHealth technology evaluation
Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessmentHealth technology evaluation
Digital technologies to support asthma self-management: early value assessmentHealth technology evaluation
Digital technologies to support smoking cessation in secondary care patients: early value assessmentHealth technology evaluationTBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All